Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 26;4(10):2158-2162.
doi: 10.1182/bloodadvances.2020001450.

Bilateral retinal detachment after chimeric antigen receptor T-cell therapy

Affiliations

Bilateral retinal detachment after chimeric antigen receptor T-cell therapy

Christopher C Denton et al. Blood Adv. .

Abstract

  1. CAR T-cell targeting of leukemic infiltrates in the optic nerve and retina caused retinal detachment as a presentation of pseudoprogression.

  2. Treatment of this intraocular inflammation with intravitreal triamcinolone and orbital radiation led to marked improvement in visual acuity.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Ocular findings at presentation and following treatment with CAR T-cell therapy. (A-D) Color fundus photography and fluorescein angiography at presentation. (A) The right eye features optic disc infiltration and leukemic retinal infiltrates and hemorrhages. (B) The left eye has leukemic disc infiltration, as well as scattered retinal infiltrates sparing the macula. (C) Fluorescein angiography of the right eye shows minimal perfusion of the choroidal and retinal circulations. (D) The left eye has relatively maintained choroidal and retinal vascular filling, with blockage in areas of leukemic infiltration and hemorrhage. (E-F) Color fundus photography following CAR T-cell therapy. The right (E) and left (F) eyes demonstrate worsened retinal whitening, hemorrhages, and optic disc edema with total exudative retinal detachments. (G) Ocular ultrasound of the right eye demonstrates subretinal fluid (arrowhead) without evidence of choroidal involvement. (H) Flow cytometry of the right aqueous humor demonstrates a predominance of CD3+CD19 cells.
Figure 2.
Figure 2.
Multimodal retinal imaging at 18 months post–CAR T-cell therapy. (A) The right eye has severe optic disc pallor, diffuse retinal atrophic changes, and sclerotic vessels. (B) The left eye has moderate-severe optic disc pallor and retinal atrophic changes. (C-D) The retina is entirely attached in both eyes. Fundus autofluorescence shows bilateral stippled and nummular areas of hyper- and hypoautofluorescence representing areas of photoreceptor and retinal pigment epithelium damage. Late-phase fluorescein angiography reveals peripheral window defects in the right eye (E) that are more common than in the left eye (F) with staining of the disc bilaterally. (G) Spectral-domain optical coherence tomography shows diffuse photoreceptor loss in the right macula. (H) The left macula has relative preservation of the photoreceptor bands and corrugation of the inner retina.

References

    1. Gardner RA, Finney O, Annesley C, et al. . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322-3331. - PMC - PubMed
    1. Maude SL, Laetsch TW, Buechner J, et al. . Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448. - PMC - PubMed
    1. Maude SL, Frey N, Shaw PA, et al. . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517. - PMC - PubMed
    1. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res. 2015;21(6):1248-1257. - PubMed
    1. Mueller KT, Waldron E, Grupp SA, et al. . Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175-6184. - PMC - PubMed

Publication types

MeSH terms

Substances